Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (4760)	1/19/1998 12:54:00 AM
From: Cacaito	Respond to of 23519

Tunica, MCA and FDA approval should not be more than burocratic problems, they already showed they could do it. I mean they were cited for minor problems in the past and they solved it. Building new units? This is different, so far they just recycled the old units and mess up production. Maybe they should pay top dollars from their "cash equivalents" and go ahead and build fast as you said. If anything approaching First Call estimates happens in the first quarter ($0.09) and they are counting with very late MCA/FDA approval then this VVUS is going to $5, The Street does not tolerate any of Vivus problems, even if unreal. So as much as I am holding my now 1/4 position, and not willing to go with my other 1/4 cash position (the other half is gone), till I see the MCA approval. No problem, I will miss the pop up, but I will see the rest of the upside. Time is for the longs, but the ride is tough. The bears are counting in the company mistakes and so far they made mone so they are willing to tolerate.